Vendor Intelligence Report: Trusted Peptide

Published 14 Jun 2026. 20-page investigative report on who is behind Trusted Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Trusted Peptide’s Finnrick record is favorable but very narrow: across 2 Finnrick lab tests, the vendor has 2 pass / 0 fail — an overall pass rate of 100%. Both tests are for Tirzepatide, making this a testing-supported choice only in that lane; the record does not validate BPC-157, TB-500, Semaglutide, or the rest of the storefront.

The vendor-level file is less clean than the Tirzepatide signal. The site names TRP LLC dba Trusted Peptide as the operator, while Florida records in the report show that same entity administratively dissolved shortly after the current .net domain was registered. A Delaware search produced no replacement record in the captured trail, leaving a governance and buyer-recourse gap rather than a simple paperwork mismatch.

Testing documentation is also mixed. Trusted Peptide posts Vanguard Laboratory COAs, and the lab itself is legitimate; however, the captured certificates are static images, lack QR or Verified-by-Vanguard backing, and use a Sheridan, Wyoming address the report treats as a virtual-mailbox signal rather than proof of a facility. The predecessor .com domain trail, now parked, adds brand-control risk because vendor promotions previously used that address.

For buyers, the practical read is not avoid everything. Tirzepatide has direct positive testing; BPC-157 carries an additional provenance caution because the product page includes a Cyrillic “ВРС-157” artifact, and untested catalog items should be treated as unsupported by Finnrick data. The report also maps the thin independent-review footprint and a promotion scan dominated by vendor self-posts rather than a mature community record.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with the Tirzepatide record and methodology-divergence charts
  • Florida TRP LLC records, Delaware no-record capture, and website policy exhibits naming TRP LLC
  • Timeline of trustedpeptide.com to trustedpeptide.net using Wayback, WHOIS, certificate, and hosting artifacts
  • Vanguard Semaglutide COA exhibits, verification-limit analysis, and Sheridan virtual-mailbox address review
  • BPC-157 catalog artifact and supply-chain opacity analysis, including import-record dead ends
  • Reputation and affiliate/promotion scan covering X, Trustpilot, Reddit, Knoji, and coupon-code sources

Risk assessment

  • Corporate-governance and recourse risk — high: TRP LLC dba Trusted Peptide is the site-named operating entity, but Florida records show TRP LLC was administratively dissolved on 2025-09-26.
  • Catalog-provenance and shipping-transparency risk — high: COA address is a Sheridan virtual-mailbox hub, no verified facility or import records were found, and BPC-157 shows a Cyrillic catalog artifact.
  • Brand-confusion and COA-verification risk — medium: Older vendor promotion used trustedpeptide.com, now parked, while the current site is trustedpeptide.net; captured Vanguard COAs lack QR/Verified-by-Vanguard verification.
  • Thin independent-reputation risk — medium: No Trustpilot profile, no organic Reddit review footprint, and promotion is dominated by vendor self-posts despite favorable but narrow Finnrick Tirzepatide data.